Definitiveradiotherapy (RT) is an excellent option for men with prostate cancer (PCa). However approximately 50% of men will develop biochemical failure, and of these, a significant minority will only have local recurrence (LR). There are several localsalvage treatment options for men whohad LR followingdefinitive RT for intact PCa, with brachytherapy being the most extensively investigated approach. However, these are infrequently used/ offered to men in the current Australian setting. Stereotactic body radiotherapy (SBRT) has emerged as a potential option for these men. We aim to...

We conducted a literature search in PubMed and MEDLINE using a series of keywords: ‘stereotactic radiotherapy’, ‘local recurrence’, and ‘prostate cancer’. Previous radiotherapy details, dose/ fractionation and technique for SBRT, PSA response, and toxicity outcomes in each study were critically appraised.

A total of 6 studies were included in this review. Baseline characeristics A total of 141 patients were included in this review Majority of patients had EBRT (116/141),2 had EBRT and brachytherapy, and 23 had brachytherapy alone The reported median EBRT dose ranged from 73.8Gy to 80Gy. The median interval between curative radiotherapy and SBRT reirradiation ranged from 13.5 to 115 months 59-100% of patients had biopsy confirmation of LR All studies reportd the use of combinatin of magnetic resonance imaging (MRI), and positron emission...

Current literature suggest that SBRT is a feasible salvage reirradiation option for men with LR following definitive RT for intact PCa, with acceptable toxicities. The advent of technology such as MRI-Linac, will provide improved soft tissues delineation and tighter target volume, thus offering us opportunities to further dose-escalate for better local control, and potentially further reduce toxicities in the SBRT reirradiation settings.

1. 2. 3. 4. 5. 6.